2nd Respiratory Medicine Department, University of Athens, Attikon Hospital, Rimini 1, 12462, Chaidari Athens, Greece.
1st Respiratory Medicine Department, University of Athens, Sotiria Hospital, Mesogeion 152, 11527, Athens, Greece.
Lung. 2018 Apr;196(2):201-205. doi: 10.1007/s00408-018-0099-5. Epub 2018 Feb 14.
Surfactant proteins (SPs) have been studied in COPD patients as biomarkers of disease severity and as predictive factors of unfavorable outcomes. The aim of this exploratory study was to evaluate serum levels of SP-A, SP-B, SP-C, and SP-D in patients with COPD both during AECOPD and in stability and to test their possible associations with disease severity and with the development of new exacerbation events. 20 consecutive COPD patients hospitalized for AECOPD were included. Serum SP levels were measured on admission, at discharge, and on stability. SP-A levels were significantly lower both on admission and at discharge in patients with early relapse compared to those with late or no relapse (29.2 ± 9.1 vs. 43.9 ± 16.9 ng/ml, p = 0.037, and 24.3 ± 2.8 vs. 39.3 ± 14.2 ng/ml, p = 0.011, respectively). SP-B levels were found to have a trend to be higher at discharge and significantly higher on stability in patients experiencing an early relapse compared to those with late or no relapse (52.5 ± 31.6 vs. 31.4 ± 32.3 ng/ml, p = 0.052 and 64.8 ± 32.6 vs. 32.8 ± 25.6 ng/ml, p = 0.024, respectively). Finally, the ROC analysis showed that serum SP-A, SP-B, and SP-C levels at discharge, seemed to be significant predictors of early relapse. Our conclusion is that serum levels of SPs might be related to disease outcomes in COPD patients.
表面活性蛋白（SPs）在 COPD 患者中作为疾病严重程度的生物标志物和不良结局的预测因素进行了研究。本探索性研究的目的是评估 AECOPD 期间和稳定期 COPD 患者血清中 SP-A、SP-B、SP-C 和 SP-D 的水平，并测试它们与疾病严重程度和新发加重事件发生的可能相关性。共纳入 20 例因 AECOPD 住院的 COPD 患者。入院时、出院时和稳定时测量血清 SP 水平。与晚期或无复发的患者相比，早期复发的患者入院时和出院时 SP-A 水平显著降低（29.2±9.1 vs. 43.9±16.9 ng/ml，p=0.037 和 24.3±2.8 vs. 39.3±14.2 ng/ml，p=0.011）。出院时 SP-B 水平有升高趋势，早期复发的患者稳定时显著高于晚期或无复发的患者（52.5±31.6 vs. 31.4±32.3 ng/ml，p=0.052 和 64.8±32.6 vs. 32.8±25.6 ng/ml，p=0.024）。最后，ROC 分析显示，出院时血清 SP-A、SP-B 和 SP-C 水平似乎是早期复发的显著预测因子。我们的结论是，血清 SP 水平可能与 COPD 患者的疾病结局有关。
